Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Cyclacel Pharmaceuticals , Inc. (NASDAQ:CYCC), currently trading at $0.33 per share with a market capitalization of $7.29 million, held its 2025 annual meeting of shareholders on June 30, 2025, according to a statement based on a recent SEC filing. InvestingPro analysis indicates the stock is currently trading below its Fair Value, presenting a potential opportunity for value investors.
At the meeting, shareholders re-elected five directors—Datuk Dr. Doris Wong, Kiu Cu Seng, Kwang Fock Chong, Dr. Satis Waran Nair Krishnan, and Inigo Angel Laurduraj—to serve three-year terms expiring at the 2028 annual meeting or until their successors are appointed. Each director received at least 99.97% of votes cast in favor, with no votes against and abstentions ranging from 15,922 to 100,082 shares. The company maintains a current ratio of 5.6, indicating strong short-term liquidity position.
Shareholders also approved an amendment to Cyclacel’s 2018 Equity Incentive Plan, increasing the number of shares of common stock available for awards by 4,281,987. The proposal passed with 99.94% of votes in favor, 0.05% against, and 0.01% abstaining.
In addition, shareholders approved, by advisory vote, the compensation of the company’s named executive officers and directors as disclosed in the proxy statement. The advisory vote received 99.95% approval, with 0.04% against and 0.01% abstaining.
Cyclacel Pharmaceuticals’ common stock and preferred stock trade on the Nasdaq Capital Market under the symbols CYCC and CYCCP, respectively.
All information is based on a press release statement and the company’s Form 8-K SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.